Lewes, DE -- (SBWIRE) -- 03/18/2014 -- The epilepsy therapeutics market value in the eight major countries - the US, Canada, France, Germany, Italy, Spain, the UK and Japan - will increase from $3.4 billion in 2012 to $4.5 billion by 2019, at a modest Compound Annual Growth Rate (CAGR) of 3.9%.
According to the report, the US will grow at a higher CAGR of 4.8%, climbing from $1.9 billion in 2012 to $2.6 billion by 2019. Meanwhile, the five European countries and Canada will achieve a combined, smaller CAGR of 3.1% during the forecast period.
Research attributes the anticipated market expansion to new Anti-Epileptic Drugs (AEDs) that have been approved during the last five years. However, further growth will be limited by the recent patent expiration of key AEDs, such as Keppra (levetiracetam) and Lamictal (lamotrigine).
Senior Analyst of this report, says: “The epilepsy treatment arena has historically been dominated by Gamma Aminobutyric Acid modulators and ion channel blockers, although a sizeable proportion of patients don’t respond to these existing treatment options.
“Second-generation AEDs, including levetiracetam, zonisamide and Vimpat (lacosamide), have signalled a shift in this trend in the last decade, with improved tolerability and safety through the use of new mechanisms of action. Recent approvals of Fycompa (perampanel) and Trobalt (retigabine) have continued this innovation by focusing on new molecular targets.”
With most of the molecules being approved in the last few years, the current epilepsy pipeline is very weak. Phase III trials account for 18% of the overall pipeline, but the majority of these late-stage molecules are reformulations or line extensions of existing drugs.
“Furthermore, the recent epilepsy pipeline does not boast drugs with novel mechanisms of action, which are considered by most prescribers as an urgent need in epilepsy therapeutics today,” analyst concludes.
This report provides a comprehensive review of the epilepsy pipeline, including individual analysis of promising late-stage pipeline drugs that are most likely to enter the market during the forecast period. Additional clinical trial analysis by Phase, trial size, trial duration and program failure rate for each molecule type and mechanism of action is also included.
For report pricing and TOC please visit: http://www.marketresearchreports.com/gbi-research/epilepsy-therapeutics-major-developed-markets-2019-new-aeds-novel-mechanisms-action
Browse other reports in therapeutic section: http://www.marketresearchreports.com/therapeutic
Current offers are going on pharma reports visit this link for more information: http://www.marketresearchreports.com/special-offers
About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.
For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter
Follow us on Twitter: https://twitter.com/MyMarketReports